Episode 387: 398. Which is Better, Tirzepatide or Semaglutide? episode artwork

EPISODE · May 21, 2025 · 8 MIN

Episode 387: 398. Which is Better, Tirzepatide or Semaglutide?

from Questioning Medicine · host Questioning Medicine

https://www.nejm.org/doi/10.1056/NEJMoa2416394At 72 weeks, the mean percentage decrease in weight was significantly greater with tirzepatide than with semaglutide (20% vs. 14%). Gastrointestinal side effects occurred frequently in both groups but led to discontinuation of treatment in only 3% and 6% of participants in the tirzepatide and semaglutide groups, respectively. Injection-site reactions were more common with tirzepatide than with semaglutide (9% vs. <1%) but didn't cause participants to stop treatment.

Episode metadata supplied by the publisher feed · Published May 21, 2025

Embed this episode

NOW PLAYING

Episode 387: 398. Which is Better, Tirzepatide or Semaglutide?

0:00 8:38

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Questioning Medicine?

This episode is 8 minutes long.

When was this Questioning Medicine episode published?

This episode was published on May 21, 2025.

Can I download this Questioning Medicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!